APA (7th ed.) Citation

LL, H., SA, I., SM, T., M, C., T, P., B, S., . . . S, K. (2025). Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. European journal of cancer (Oxford, England : 1990), 217, 115225. https://doi.org/10.1016/j.ejca.2025.115225

Chicago Style (17th ed.) Citation

LL, Hart, et al. "Efficacy, Safety, and Patient-reported Outcomes Across Young to Older Age Groups of Patients with HR+/HER2- Advanced Breast Cancer Treated with Ribociclib Plus Endocrine Therapy in the Randomized MONALEESA-2, -3, and -7 Trials." European Journal of Cancer (Oxford, England : 1990) 217 (2025): 115225. https://doi.org/10.1016/j.ejca.2025.115225.

MLA (9th ed.) Citation

LL, Hart, et al. "Efficacy, Safety, and Patient-reported Outcomes Across Young to Older Age Groups of Patients with HR+/HER2- Advanced Breast Cancer Treated with Ribociclib Plus Endocrine Therapy in the Randomized MONALEESA-2, -3, and -7 Trials." European Journal of Cancer (Oxford, England : 1990), vol. 217, 2025, p. 115225, https://doi.org/10.1016/j.ejca.2025.115225.